Alto Neuroscience
Market cap $999M 40.1M shares (10-Q, Nov 5, 2026) × $24.91 close Nov 17, 2026
Most recent annual filing: 2026-03-16
- ALTO-207 filingLate 2026 / early 2027ALTO-207 filing, Late 2026 / early 2027, material
- COMP360 Compass NDA filingNov 2026COMP360 Compass NDA filing, Nov 2026, notable
- ANRO general corporate updateNov 19, 2026ANRO general corporate update, Nov 19, 2026, routine
- ALTO-300 Ph2b topline1H 2027ALTO-300 Ph2b topline, 1H 2027, major
- PACE-2 Ph3 startEarly 2027PACE-2 Ph3 start, Early 2027, notable
- ANRO financing corporate updateJan 1, 2027ANRO financing corporate update, Jan 1, 2027, routine
- ALTO-100 Ph2b toplineMid-2027ALTO-100 Ph2b topline, Mid-2027, major
- PACE-1 topline2H 2027PACE-1 topline, 2H 2027, thesis-defining
- PACE-3 Ph3 start2H 2027PACE-3 Ph3 start, 2H 2027, notable
- ANRO CFO corporate updateAug 2027ANRO CFO corporate update, Aug 2027, routine
- ANRO lease corporate updateOct 31, 2027ANRO lease corporate update, Oct 31, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
ALTO-100
ALTO-203
ALTO-207
ALTO-208
ALTO-202
Technology platforms
Precision Psychiatry Platform
Proprietary biomarker discovery and patient stratification platform combining EEG, neurocognitive assessments, wearable devices, and genomic data with machine learning analytics to identify brain-based biomarkers for psychiatric drug development. Focus areas include major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson's disease.
Discontinued (2)
- ALTO-101 — Cognitive Impairment Associated with Schizophrenia · missed primary endpoint; company will not independently advance ALTO-101 in CIAS
- ALTO-100 — Major Depressive Disorder · Phase 2b study did not meet its primary endpoint in MDD; development continued in BPD instead
Capital (as filed)
- Cash
- $319M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$20.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $320M cash, runway through 2030 per the deep dive of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (1)
- 2026-11-17 Alto Neuroscience (ANRO) - Scientific Deep Dive for ALTO-207 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (1 call)
Every verdict Biotech Distilled has published on Alto Neuroscience, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-11-17 Watch Alto Neuroscience (ANRO) - Scientific Deep Dive for ALTO-207 and Pipeline Products Pramipexole's antidepressant effect is well-validated but at ~$1.1B EV the stock already prices a likely PACE-1 win, ALTO-207's own data are thin (32 patients, single-blind, secondary endpoint), and the moat around two generic drugs rests on method claims expiring ~2038-2039 with no NCE exclusivity.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (19)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. No press release captured yet; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 10, 20268-KCurrent report: results of operations · EX-99.1
- Nov 10, 202610-QQuarterly report
- Aug 27, 20268-KCurrent report: officer / director change
- Aug 12, 20268-KCurrent report: results of operations · EX-99.1
- Aug 12, 202610-QQuarterly report
- Jul 14, 20268-KCurrent report: material agreement
- Jul 14, 2026424B5Prospectus supplement (offering)
- Jul 13, 20268-KCurrent report: results of operations, other events
- May 28, 20268-KCurrent report: officer / director change
- May 13, 20268-KCurrent report: officer / director change, shareholder vote
- May 13, 20268-KCurrent report: results of operations · EX-99.1
- May 13, 202610-QQuarterly report
- Apr 10, 2026S-3Shelf registration
- Apr 1, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- Mar 26, 2026DEFA14AProxy soliciting material
- Mar 26, 2026DEF 14AProxy statement
- Mar 16, 20268-KCurrent report: results of operations · EX-99.1
- Mar 16, 20268-KCurrent report: material agreement, unregistered sale of equity, other events · EX-99.1 EXHIBIT 99.1
- Mar 16, 202610-KAnnual report
15 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Oct 30, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jul 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 20, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 20, 2026EFFECTRegistration effective
- Apr 17, 2026CORRESPCORRESP
- Apr 16, 2026UPLOADUPLOAD
- Mar 26, 2026ARSAnnual report to shareholders
- Mar 16, 2026S-8Employee plan registration